Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective
International Journal of Dermatology · 21.05.2026
DOI: 10.1111/ijd.70491 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Dermatology, online erschienen am 21.05.2026. Verfasst von Francisco Javier Melgosa Ramos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Bimekizumab shows high efficacy in moderate‐to‐severe hidradenitis suppurativa, achieving deep clinical responses and improving structural lesions such as draining tunnels. However, mucocutaneous candidiasis is the most characteristic adverse event due to IL‐17 pathway inhibition, although it is usually mild and manageable. Based on clinical experience, a proactive, risk‐adapted approach including targeted antifungal strategies may improve tolerability. This perspective supports shifting from reactive to preventive management to optimize long‐term treatment persistence.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, University Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain.
- Department of Dermatology, Marina Baixa Hospital, Alicante, Spain.
- Department of Dermatology, Hospital Virgen de los Lirios, Alicante, Spain.
- Department of Dermatology, Hospital General Universitario, Valencia, Spain.
- Department of Dermatology, Hospital del Mar, Barcelona, Spain.
- Department of Dermatology, Hospital de Manises, Valencia, Spain.
ORCID-Profile: Francisco Javier Melgosa Ramos, Antonio Martorell
Zitieren
APA
Melgosa Ramos, F. J., Mataix, J., Santos Alarcón, S., Ortiz Salvador, J. M., Martín Ezquerra, G., & Martorell, A. (2026). Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective. International Journal of Dermatology. https://doi.org/10.1111/ijd.70491
Vancouver
Melgosa Ramos FJ, Mataix J, Santos Alarcón S, Ortiz Salvador JM, Martín Ezquerra G, Martorell A. Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective. International Journal of Dermatology. 2026. doi:10.1111/ijd.70491
BibTeX
@article{MelgosaRamos2026,
author = {Melgosa Ramos, Francisco Javier and Mataix, Javier and Santos Alarcón, Sergio and Ortiz Salvador, Jose María and Martín Ezquerra, Gemma and Martorell, Antonio},
title = {Targeted Prevention and Management of Mucocutaneous Candidiasis During Bimekizumab Therapy in Hidradenitis Suppurativa: A Practical Clinical Perspective},
journal = {International Journal of Dermatology},
year = {2026},
doi = {10.1111/ijd.70491}
}
EUVIMED